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Xguidelines and found them to be frequent and have minor to
no impact on outcomes. Ideally, the findings of these series
may give clinicians more confidence when deciding to ac-
cept donor lungs that are not ‘‘ideal.’’ Interestingly, as docu-
mented in this series, this decision to use donor lungs with
a PaO2 of less than 300 mm Hg is being made already in
nearly a fifth of all LTxs being performed in the United
States. The decision to use lungs with less than ideal char-
acteristics will only become easier in the next few years
as ex vivo lung perfusion will allow these ‘‘marginal’’ donor
lungs to be reassessed and optimized before implantation.
Donor PaO2 does not appear to affect pulmonary graft
survival. Therefore, this result appears to provide an oppor-
tunity to substantially increase the donor lung pool and be-
gin to rebalance the donor–recipient imbalance. We are not
suggesting that donor PaO2 is not important when assessing
potential lung donors, but its level of importance in regard
to other criteria appears less than previously believed.References
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Dr Thomas K. Waddell (Toronto, Ontario, Canada). Dr Mo-
rales, thank you for an interesting analysis and for sending the pa-
per in advance.
The subject of appropriate criteria for acceptance of the donor
lung has been extensively discussed, and there is a consensus
that many usable organs are ultimately rejected for poorly evalu-
ated criteria. You are to be congratulated for revisiting this issue.
Increasingly sophisticated analyses have been brought to bear,
and this is one of my major concerns regarding your paper. Two
approaches were taken in this analysis. One was to divide the co-
hort into 4 groups, and there was no difference in survival using
a log–rank analysis. In the second analysis you took all 21 donor
variables that were available and put them into a multivariable
analysis. Once again, donor PaO2 was not statistically significant.
Why did you not deal with the subject of recipient covariants?
You did show in the first analysis that there were no major differ-
ences. However, I would refer you to a very interesting analysis by
Reyes from the Cleveland Clinic published in The Annals of Tho-
racic Surgery in June of 2010 that took essentially the same data
set from UNOS and came to very different conclusions. In partic-
ular, Reyes’ group showed that a PaO2 of less than 230 mmHgwas
a problem. Even more emphatically, there was an analysis by Hen-
nessy from the University of Virginia group that took the UNOS
data from an even larger data set and found that there was in fact
an adverse effect of high PaO2. Thus we have 3 analyses from
the same data source that have come to 3 different conclusions.
In particular, yours is one that does not have any correction for re-
cipient characteristics, and I wonder if you could address why not.
DrMorales. The fact that 3 different conclusions have been de-
rived from the same database will demonstrate that it is probably
unclear whether donor PaO2 really does have an effect on graft sur-
vival. Three different institutions have looked at it and have not
come up with a consistent finding. We thought that we accounted
for recipient characteristics with the fact that when we analyzed
them in subgroups, they really did not differ clinically. These
things did not really differ by age or by weight, except for the
fact that more double LTxs were done with donors who had
a PaO2 that was lower. Thus I think that we did look at recipient
characteristics in our different subgroups.
Dr Waddell. Some of the recipient characteristics that you
looked at were not actually the ones that are most tightly linked
to outcome, and that would be a limitation.
My second question concerns what I consider to be one of the
more interesting findings, and you did not really remark on it.
The statistically significant donor variable that was associatedrdiovascular Surgery c Volume 143, Number 4 923
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Xwith poor outcome was in fact steroid use. You could make the
similar argument in your introduction that steroid use in the donor
was introduced with very little evidence base, and I found it inter-
esting that the use of steroids was associated with a hazard ratio of
1.7, meaning quite bad for long-term outcome. Do you want to
speculate on why that might be? Do you think we need to revisit
the use of steroids? Do you think we should do a randomized trial
to evaluate it?
Dr Morales. Thank you for your comments.
I did not put that in the presentation, but it is true that steroid use
did come out in the analysis. My transplant program thought long
and hard about why that would be, and we were not quite sure, es-
pecially since in the ex vivo protocols, we are now using steroids
during that time to help recover the lung.
Dr Bryan F. Meyers (St Louis, Mo). Right now I think LTx is
a luxurious therapy. With the amount of benefit it provides, it is
very expensive, both to do it and tomaintain the patients afterward.
Future analysis on something like this has to look at the efficiency
of the procedure as well as the early outcomes of survival or non-
survival. It we take perfect lungs and use them, we are going to get
a certain baseline outcome for a baseline expenditure. As we begin
using more risky lungs, we will encounter a more complex and
more expensive perioperative course. The likelihood of bypass
and extracorporeal membrane oxygenation will increase. The
risk of acute retransplantation will increase, and the longer-term
benefit will be diminished as well. I think that your first cut on
this is useful and thought-provoking. However, we need to get be-
yond just the most elemental evaluation of something like the do-
nor PaO2 and look at the incremental cost and the incremental
benefit that we would get by extending the use of donors that are
less than optimal.
DrMorales. Thank you for your comments. I agree. Things like
the UNOS database, the Nationwide Input Sample database, and
other administrative databases are problematic in that they only
supply short-term follow-up. We are starting, especially with
The Society of Thoracic Surgeons database, to think of linking
these to longer-term follow-ups, such as the Social Security Death
Master File or the National Death Index, from which long-term
mortality can be obtained. If something like the UNOS database
could be connected it to the Social Security Death Master File,
then the long-term effect of donor PaO2 on these grafts could be
determined. I think that should be a way to empower most of
our surgical databases, which are always limited by the fact that
we do not have long-term follow-up.
Dr Marcelo Cypel (Toronto, Ontario, Canada). I have 1 com-
ment and 2 quick questions.
One of the major problems with these data is that the PaO2 was
collected before you opened the chest and recruited the lungs. I
would imagine with the 20%, it would be a much smaller number
that would actually have a PaO2 less than 300 when you have op-
timized conditions.
My first question is this: what do you mean by graft survival
here, and why didn’t you use the ISHLT primary graft dysfunction
scores? I am not sure what graft survival means in days, as you
showed there.
The second question is whether you see a correlation of the im-
plementation of the lung allocation score with the increased num-
bers of lungs being assessed with PaO2s less than 300 mm Hg.924 The Journal of Thoracic and Cardiovascular SurgDr Morales. To answer your questions, we did not look at the
lung allocation score. By graft survival, we mean survival either
to retransplantation or to death. I do realize, and I mentioned this
as a limitation, that obviously you could have a PaO2 of 300 or
250, then take them to the operating room, recruit the lungs, and
thenfind that the PaO2 is 400.But I think it is surprising. Ifwe polled
everyone before we gave this presentation and asked what percent-
age of people in the UNOS database has a PaO2 less than 300, I’m
not sure many people would have said 20%. I think it just brings up
the fact that we have all grown up talking about PaO2s over 300, but
that level is not really established in any real data, and so I think it is
thought-provoking. Again, I also think when you get a donor call
and the first PaO2 is 200 mm Hg on 100% FiO2, unless your recip-
ient is very sick, many people would not think these lungs were ac-
ceptable. Perhaps this study will make people think a little bit more
about whether such lungs might be usable.
Dr Ankit Bharat (St Louis, Mo). Thank you for an interesting
presentation.
One of my concerns is that you demonstrated that there is no
difference in the long-term graft survival, and I presume this is
looking at chronic rejection. We know chronic rejection has a mul-
tifactorial pathology and is affected by multiple other variables. I
was wondering whether you looked at the short-term or the acute
events, such as development of primary graft dysfunction, sepsis,
and things like 30-day mortality in these patients and found any
effects in patients who had low PaO2s compared with those who
had lungs with a better PaO2. My second question is, if there
were such differences, is it possible that the differences in treat-
ment between these 2 groups of patients in the short term affected
their long-term survival and development of chronic rejection?
Dr Morales. The 2 things that we did look at were acute rejec-
tion in the hospital and length of stay, neither of which was statis-
tically different between the 2 groups. You are right. Perhaps if you
took a set of lungs with a PaO2 that was 250, you would take per-
haps better care of those lungs postoperatively. Obviously, I cannot
comment on that through a database.
Dr Joel D. Cooper (Philadelphia, Pa). I rise to discuss a point
in history. I enjoyed your paper very much.
The 300 mm Hg level is something that we inherited as well, in
the early days. I must say that I learned a great deal from the Stan-
ford group about heart–lung transplants. When we began getting
into heart–lung and lung transplants, we visited there and tried
to learn as much as we could from them. Perhaps that is where it
arose. I would also point out that in the early days, we and others
did everything possible to eliminate any adverse effects of donor
lung ischemia. We only used donors from our own city, we only
used very short ischemic times, and, yes, we only used donors in
whom the PaO2 was greater than 300 mm Hg, because at least
that is what I was advised. Obviously, as a procedure matures,
you are willing to take more risk, you do not believe that the whole
future of LTx rests in having every case successful, and you are
willing to use more marginal donors. I do not know where it arose,
and it was just an arbitrary standard, which seemed to be a very
high standard. We wanted to reduce as much as possible any ad-
verse factors that might affect the outcome in those early days.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). There is
a point, DrMorales, that still concerns me. There have been at least
2 previous major analyses of about 10,000 patients, plus or minusery c April 2012
Zafar et al Cardiothoracic Transplantation1000, looking at this fact. As you and Dr Waddell mentioned, they
came to different conclusions. That does not tell me that the PaO2
is not as important as we used to think. That may well be true, but it
speaks more to errors that we could make in throwing out a blanket
statement, like: ‘‘Don’t worry about PaO2 because it didn’t come
out as a significant factor.’’ I think it speaks also to the quality of
the data. What you have shown again is that lungs were used suc-
cessfully that at some point in the donor journey got a low PaO2
recorded by some coordinator in the middle of the night some-
where in the United States. That does not necessarily tell you
that PaO2 is not important. Again, it may not be as important,The Journal of Thoracic and Caand we are learning more about that and studying it, but I would
not think that that is a valid statement to make from the data that
you were working with.
DrMorales.Asmy conclusions stated, I am not actually stating
that donor PaO2 is not important, but how critical it is for predicting
graft survival especially at the level of 300 mm Hg is unclear.
Through the data that we analyzed, this is what we can conclude.
Again, I do not believe that we should not be concerned about
the donor PaO2, but its level of importance or the level of donor
PaO2 that is acceptable is something that we need to think about
and question.rdiovascular Surgery c Volume 143, Number 4 925
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